May 24, 2000
Fines Proposed for Violations of
Human Research Rules
By SHERYL GAY STOLBERG
WASHINGTON, May 23 -- Responding to widely publicized lapses in
medical experiments, the Clinton administration announced today that it
would seek authority from Congress to levy fines of up to $250,000 on scientists
who violate federal rules for human research and $1 million on the universities
that employ them.
The proposed fines are part of a broad plan, unveiled this morning by
Donna E. Shalala, the secretary of health and human services, to better
protect the thousands of patients who each year volunteer for medical experiments,
including tests of new drugs and cutting-edge treatments like gene therapy.
It comes two days before officials are to testify at a Senate hearing on
patient safety.
Under the plan, which President Clinton described today as "a critical
first step" toward improving patient safety, the government will require
bioethics training for clinical researchers and will lay down clear conflict-of-interest
guidelines for doctors who have financial stakes in their studies.
There will be new requirements for monitoring small clinical experiments,
which are not subjected to the same intense regulatory scrutiny as larger
studies. And, Dr. Shalala said, research institutions will now be required
to audit records for proof that patients have truly given their "informed
consent" to participate.
"This is a clear message that we intend to get serious," Dr. Shalala
said. Saying she is concerned about maintaining public confidence in medical
research, she added, "We have to make sure that the entire enterprise is
rigorous and has enormous integrity."
With the exception of the move to assess fines, which requires Congressional
action, Dr. Shalala said the initiatives outlined today would take effect
immediately. Her announcement brought praise from Dr. Nils Hasselmo, president
of the American Association of Universities, who called it a "constructive
action."
But punishing scientists with fines is bound to be controversial, and
may face trouble on Capitol Hill. Senator Bill Frist, the Tennessee Republican
who has been leading a Congressional examination of federal research protections,
said today that the idea struck him as "somewhat premature." And it provoked
a strong reaction in some academic quarters.
"It's radical and it's inappropriate," said Dr. Gerald S. Levey, dean
of the medical school at the University of California at Los Angeles. He
added, "It will drive people out of doing clinical research and, I think,
cause a great deal of chaos."
At a morning press briefing to make the plan public, Dr. Shalala was
flanked by Dr. Jane E. Henney, who heads the Food and Drug Administration,
and Dr. Ruth Kirschstein, acting director of the National Institutes of
Health. Both agencies have come under criticism for lax oversight of gene
therapy experiments, particularly after the death of an 18-year-old patient,
Jesse Gelsinger, at the University of Pennsylvania last fall.
An F.D.A. inspection cited a litany of deficiencies in the way that
experiment was run, and the agency has since shut down all gene therapy
trials at Penn, as well as certain other gene therapy studies. But the
tactic of shutting down an entire research program is draconian; some scientists
call it "the atomic bomb of research regulation." In explaining the rationale
for using fines, Dr. Henney said that while fines might sound harsh, they
would actually be an intermediate step.
Dr. George Rupp, president of Columbia University, put it this way,
in a telephone interview: "The federal government doesn't have any intermediate
actions between dropping the atomic bomb and a wrist slap. This is clearly
an effort to look for a more focused and discriminating level of penalty."
While much of the public attention has focused on gene therapy, gene
research is not the government's only safety concern. The biomedical revolution
of the last 20 years has produced countless medicines and therapies that
have allowed patients to live healthier, longer lives. But the scientific
boom has brought with it complications, Dr. Shalala said, that stretch
across the spectrum of science.
In part, this is because novel technologies like gene therapy pose new
risks. At the same time, the changing relationship between academic scientists
and industry is posing new conflict of interest problems. In addition,
the sheer volume of clinical studies makes keeping tabs on them difficult.
The patient safety infrastructure depends on hospital committees, institutional
review boards, that evaluate and approve human experiments. In a report
two years ago, the Inspector General of the Department of Health and Human
Services found that those committees are overloaded and may spend no more
than a few minutes reviewing
each study.
Dr. LeRoy H. Walters, a bioethicist at Georgetown University, cautioned
that without more money to beef up the committees, the government's new
initiatives will be of little use.
"The institutional review board system is really strained almost to
its limit," Dr. Walters said, adding that without money to help with "high
quality research review," today's announcement "may feel to local institutions
like it's the whip being cracked once again."
INFORMED CONSENT?
Is it possible that Donna E. Shalala is a hypocrite of immense proportions???
By definition, every vaccine batch produced is an experiment without
long term active surveillance large cohort scientifically controlled safety
testing.
Current vaccination policy and the entire medical-industrial-government
vaccine complex are in gross egregious violation of each and every point
that this new plan ostensibly seeks to thwart. If Ms. Shalala is serious
about rigorous informed consent and an enterprise with enormous integrity
she should immediately halt production of all vaccines and massively fine
the co-conspiring parties, starting with the manufacturers and their paid
physician/researcher cronies!
Don’t miss Shalala’s priceless quote about informed consent. Why not
start auditing all the vaccinator’s records for informed consent starting
today!
Dr. Doug Hertford, MD, MEng <dehertf@med.cornell.edu>
MEMBERSHIP RENEWALS
I want to thank all of you once
again for your support during GVAL’s first few years. Please continue to
help us put lifesaving information in the hands of the families who are
not yet completely informed and are preparing to vaccinate their children.
Everyday GVAL receives telephone calls, letters, and e-mail from families
looking for more information on vaccines and their serious side effects.
We need the support of your membership to continue the assistance to these
families. They need to hear the other side of the story as well. As a parent
who lost a child from a vaccination, I only wish that I would not have
been so conditioned and had been aware of the ever-growing concern over
this issue. I plead with you for your continued support in this most worthy
cause- the saving our children’s lives. Please renew your tax-deductible
membership today, as it may help to save a life tomorrow.
GVAL’s Advisory Board:
Dr. Viera Scheibner, Research Scientist
Dr. Hashem Cyrus, Neurosurgeon
Dr. Richard Lindwall, Chiropractor
Lawrence Harris, Attorney at Law
Reverend Bill Gaddie
If you have any questions or comments
please feel free to contact us at the following address:
Global Vaccine Awareness League
25422 Trabuco Rd.,
Suite 105-230
Lake Forest, CA 92630-2797
E-mail: Michelle@gval.com
http://www.gval.com/
"The best decision is an informed
decision"
Send
Mail to GVAL |